Hepatocyte growth factor activator inhibitor

Abstract: A novel protein having inhibitory activity on the protease activity of hepatocyte growth factor (HGF) activator was purified and isolated, and its molecular weight (ca. 30,000 daltons) and partial amino acid sequence were determined. A gene coding for the protein was cloned, and the gene DNA was incorporated into a vector, for transforming host cells. Cultivation of the transformant gave the desired protein. The protein can be used as an in vivo or in vitro control factor for HGF or HGF activator. It is also useful as an antigen to be used in producing an antibody to be used as means for kinetic studies of the protein, or as a standard in assay systems therefor.

Description: The present invention relates to a novel protein. More particularly, it relates to a novel protein having inhibitory activity on the protease activity of hepatocyte growth factor activating factor (HGF activator) (hereinafter this protein is sometimes referred to also as "HAI-II"). It is already reported that thrombin activates the precursor of HGF activator (JP-A-5-103670, JP-A-6-141859, JP-A-6-153946 and JP-A-6-153966 (the term "JP-A" as used herein means an "unexamined published Japanese patent application")); factor having activity to convert the single chain form of hepatocyte growth factor (HGF) to its double chain form) in the manner of positive activity control. However, any human tissues-derived protease inhibitor capable of inhibiting, as a negative control factor, the physiological activity of HGF activator has not been known. Therefore, how HGF activator is controlled in human tissues remains unknown. Such a negative control factor might also influence indirectly on the activity of hepatocyte growth factor (HGF) on which HGF activator acts. Thus, for the analysis of the mechanism of action of HGF in vivo , as well, it has been demanded that such a human tissues-derived protease inhibitor be isolated and identified. By using such a protease inhibitor and an antibody to the protease inhibitor, it would become possible to know the in vivo physiological activity of HGF activator, analyze the mechanism of action thereof or analyze the mechanism of control of HGF activation, from a standpoint different from those of the prior art. WO 97/33996 discloses a purified human serine protease inhibitor which can specifically inhibit kallikrein that has been isolated from human placental tissue, via affinity chromatography. EMBL/Genbank Databases Accession no R35464 Sequence reference HS46499, May 4, 1995 L. Hillier et al: 'The WashU-Merck EST Project' XP002039653 discloses a homo sapiens cDNA clone having a serine protease inhibitor activity, the sequence of which is as follows: EMBL/Genbank Databases Accession no N39798 Sequence reference HS798277, January 26, 1996 L. Hillier et al: 'The WasU-Merck EST Project' XP002039654 discloses a serine protease inhibitor activity, the sequence of which is as follows: EMBL/Genbank Databases Accession no R74593 Sequence reference HS593137, June 9, 1995 L. Hillier et al: 'The WashU-Merck EST Project' XP002039655 discloses a serine protease inhibitor activity, the sequence of which is as follows: Prior art document J Biochem 1994 Nov.; vol. 116, no. 5, pages 939-942 relates to the cDNA cloning and mRNA expression of a serine protease inhibitor secreted by cancer cells. The protein was identified as placental protein 5 and tissue factor pathway inhibitor-2. The present inventors have conducted screening of various cultured cell lines using, as an indicator, the inhibitory activity on the protease activity of hepatocyte growth factor activator and have found that a substance having the activity occurs in the culture supernatant of certain human cancer cell lines (MKN45 cells, A549 cells and like epithelial tumor cell lines). To reveal the nature of its inhibitory activity, they further attempted to purify the substance from the MKN45 cell culture supernatant using various column chromatography techniques. As a result, they have found a novel protein with a molecular weight of about 30,000 daltons as determined by SDS (sodium dedecyl sulfate)-polyacrylamide gel electrophoresis(PAGE) and, they also have obtained an amino-terminal amino acid sequence of this protein by analyzing the protein on a protein sequencer. Further, they determined partial amino acid sequences by decomposing the protein using proteolytic enzymes, isolating the resultant peptides and subjecting each peptide to the same amino acid sequence analysis as mentioned above. Furthermore, they estimated DNA base sequences based on the partial amino acid sequences and conducted screening of a cDNA library using oligonucleotide probes prepared based on the sequences. The present invention thus relates to a protein having the following physico-chemical properties: (1) inhibitory activity on the protease activity of hepatocyte growth factor activator; and (2) the amino acid sequence depicted in the sequence listing under SEQ ID NO: 2. The present invention further relates to a method of producing the above protein which comprises cultivating MKN45 cells or A459 cells under conditions contributing to the expression of the protein and isolating the protein from the culture supernatant. The base sequence shown in the sequence listing under SEQ ID NO: 4 contains only one strand, with the other complementary base sequence being omitted. Starting with this gene and using the recombinant DNA technology, it is possible to cause expression of, for example, the protein having the amino acid sequence shown in the sequence listing under SEQ ID NO: 4/5. On that occasion, the protein translated from mRNA coding for the protein contains a signal sequence. After extracellular excretion, however, the signal sequence has been cleaved off and the protein obtained has an amino acid sequence comprising the 28 th amino acid (alanine) residue and the subsequent amino acid residues of the amino acid sequence shown in the sequence listing under SEQ ID NO:4. Signal sequences of other proteins may also be used as the signal sequence. For signal sequence-free mature protein expression in host cells, a gene having that portion of the base sequence shown in the sequence listing under SEQ ID NO:4 which comprises the 82nd nucleotide (guanine) residue and the subsequent nucleotide residues may be used as the gene coding for the relevant protein and joined to the ATG codon of a vector. The present invention further includes, within the scope thereof, modifications of the proteins mentioned above as derived therefrom by deletion, substitution and/or addition of one or more amino acid or nucleotide residues within limits not harmful to the inhibitory activity on the protease activity of HGF activator, namely those proteins that respectively have "substantially equivalent amino acid sequences" Fig. 1 shows the results of assaying of the protein of the present application for its inhibitory activity on the protease activity of HGF activator. In the following, the present invention is described in further detail. The novel protein of the present invention which has protease inhibitor activity can be obtained by proceeding via such purification steps as mentioned below. For example, a human cancer cell line (MKN45 cells or A549 cells deposited with the Japanese Cancer Research Resources Bank under the deposite numbers JCRB0254 and JCRB0076, respectively, or like epitherlial tumor cell line) is cultivated in a serum-free medium for several days, the culture supernatant is recovered and, after removal of cells therefrom and concentration, submitted to a heparin-Sepharose column (available e.g. from Pharmacia). The non-adsorbed fraction is submitted to a ConA-Sepharose column (available e.g. from Pharmacia) and separated into an adsorbed fraction and an non-adsorbed fraction. The non-adsorbed fraction is subjected to hydrophobic chromatography using Phenyl-5PW (available e.g. from Tosoh Corp.). The thus-obtained fraction containing the desired protein is chromatographed on a DEAE ion exchange column (available e.g. from Polymer Laboratory), then submitted to a hydroxyapatite column (available e.g. from Mitsui Toatsu Chemicals or Seikagaku Corp.), and further to gel filtration column chromatography (using e.g. Asahi Chemical Industry's GS520) to give the protein in question. The purification steps may further include reversed phase column chromatography and/or other appropriate means, as necessary. Upon SDS-polyacrylamide gel electrophoresis, the thus-purified protein of the present invention migrates as a smear band or several fragments presumably resulting from differences in sugar chain, amino acid residue modification and/or C-terminal side mutation and having a molecular weight of about 30,000 daltons. When reacted with HGF activator, the protein shows inhibitory activity on the protease activity of HGF activator. This protein of the present invention contains the amino acid sequence shown in Table 1 below. The protease inhibitor activity-endowed protein of the present invention has inhibitory activity on the protease activity of HGF activator and, therefore, is useful as a in vitro or in vivo regulatory factor for HGF activator or, indirectly, as a HGF activity regulating factor. The protein as well as an antibody to the protein or a gene coding for the protein is further useful as a tool or means for function analysis of the factors. The present invention is now illustrated in greater detail with reference to the following Examples. However, it is not intended that the present invention be limited to these Examples. EXAMPLE 1 (Purification of the protein using an MKN45 cell culture supernatant) MKN45 cells (Naito et al., Gan to Kagaku-ryoho (Cancer and Chemotherapy), 5 , 89 (1978)) (obtained from Meneki Seibutsu Kenkyusho) were seeded into eRDF medium containing 5% FBS (fetal bovine serum) as placed in a roller bottle 850 and allowed to multiplicate until a confluent state was attained. Then, the FBS-containing culture supernatants was removed and the cells were washed with two portions of serum-free eRDF medium. After removing the washing medium, 500 ml of serum-free eRDF medium was added and incubation was carried out at 37°C for 3 to 6 days. After incubation, the culture supernatants was recovered, 500 ml of fresh serum-free eRDF medium was added, and incubation was again conducted. This procedure was repeated several times. The culture supernatants thus recovered were combined and concentrated about 20-fold using a YM30 ultrafiltration membrane (Amicon). This concentrate was submitted to a heparin-Sepharose column (equilibrated with PBS) and the non-adsorbed fraction' was recovered. This fraction was submitted to a ConA-Sepharose column (equilibrated with PBS) and separated into the non-adsorbed fraction and an adsorbed fraction eluted with a PBS solution containing 200 mM α-methyl-D-mannoside. The ConA non-adsorbed fraction was concentrated using YM30, followed by buffer substitution to 10 mM phosphate buffer (pH 6.8) containing 1 M ammonium sulfate. The new solution was subjected to HPLC using Phenyl-5PW (Tosoh Corp.; equilibrated with 10 mM phosphate buffer (pH 6.8) containing 1 M ammonium sulfate), followed by linear concentration gradient elution with 1 M ammonium sulfate to 0 M ammonium sulfate. A fraction containing the desired protease inhibitor activity was thus recovered. The fraction was dialyzed against 20 mM Tris-hydrochloride buffer (pH 8) containing 0.05% CHAPS and then subjected to HPLC using DEAE (equilibrated with 20 mM Tris-hydrochloride buffer (pH 8) containing 0.05% CHAPS), followed by linear concentration gradient elution with 0 M to 500 mM NaCl, whereby a fraction showing the desired protease inhibitor activity was recovered. The fraction was dialyzed against 5 mM phosphate buffer (pH 6.8) containing 0.05% CHAPS and then subjected to HPLC using a HCA A-4007 column (product of Mitsui Toatsu Chemicals) (equilibrated with 5 mM phosphate buffer (pH 6.8) containing 0.05% CHAPS), and the non-adsorbed fraction was recovered. The fraction was submitted to GS-520 (equilibrated with PBS containing 0.05% CHAPS) and an active fraction (fraction of about 40 to 20 kDa) was recovered. For eliminating minor bands, the fraction was applied to a YMC pack C4 column (obtained from YMC), linear concentration gradient elution was carried out over 40 minutes using acetonitrile-isopropyl alcohol (3/7) containing 0.1% TFA and varying the concentration thereof from 10% to 50%, and the active fraction was neutralized with 1 M Tris-hydrochloride buffer (pH 8) and then dried under reduced pressure. After drying, the solid obtained was dissolved in PBS containing 0.05% CHAPS to give a purified protein solution. EXAMPLE 2 (Amino-terminal amino acid sequence and partial amino acid sequence determination of the protein) The protein having protease inhibitor activity as purified as in Example 1 and eluted by reversed phase HPLC was dried under reduced pressure without neutralization. This was dissolved in 60 µl of 50% TFA (trifluoroacetic acid), added to a polybrene-treated glass filter and subjected to Edman degradation on an Applied Biosystems model 470A sequencer, and the amino acid sequence of an N-terminal region was determined. Phenylhydantoin (PTH)-amino acids were identified using a Mitsubishi Chemical's MCI gel ODS IHU column (0.46 × 15 cm) and conducting single solvent elution with acetate buffer (10 mM acetate buffer (pH 4.7), 0.01% SDS, 38% acetonitrile) at a flow rate of 1.2 ml/minute and a temperature of 43°C. PTH-amino acids were detected based on the absorbance at 269 nm. As a result, the N-terminal amino acid sequence shown below in Table 1 was identified. Then, the same protein having protease inhibitor activity as purified as in Example 1 and eluted by reversed phase HPLC was dissolved in 100 µl of 50 mM Tris-hydrochloride buffer (pH 9.0) containing 4 M urea, lysyl endopeptidase (Achromobacter protease I) was added to the solution, and the reaction was carried out at 37°C for 8 hours. The resulting peptide mixture was separated by reversed phase HPLC using a YMC pack C8 column (YMC) to give respective peptide fragments. Two peptides were subjected to amino acid analysis using a gaseous phase sequencer (Applied Biosystems model 1470A). The sequences shown in Table 1 were found. EXAMPLE 3 (Purification of the protein using an A549 cell culture supernatant and amino acid sequence analysis) A culture supernatant was prepared by cultivating A549 cells (obtained from the Japanese Cancer Research Resources Bank) in the same manner as in Example 1. Using the culture supernatant and proceeding in the same manner as in Example 1, a protein having the inhibitory activity on the protease activity of HGF activator was obtained. Upon SDS-PAGE, this protein showed the same molecular weight as that derived from MKN45 cells. When subjected to the same N-terminal amino acid sequence determination as in Example 1, this protein gave the same sequence as that of the MKN45 cell-derived protein. This suggested the possibility of the protein being identical with the MKN45-derived protein. EXAMPLE 4 (Method of assaying the activity of the protein inhibiting the protease activity of HGF activator as well as the activity) One to ten µl of the sample to be assayed was added to 30 to 40 µl of PBS-0.05% CHAPS solution containing 2 to 5 ng of serum-derived HGF activator. After 30 minutes of incubation at 37°C, 5 to 10 µg of single chain HGF was added and incubation was further continued for 2 hours. This incubation mixture was subjected to SDS-polyacrylamide gel electrophoresis under reducing conditions. After electrophoresis, Coomassie Brilliant Blue R250 (CBB) staining was performed and the proportions of single chain HGF and double chain HGF were compared for activity detection. The purified protein (10 ng) and 5 ng of serum-derived HGF activator were incubated in 30 to 40 µl of PBS-0.05% CHAPS solution at 37°C for 30 minutes, then 10 µg of single chain HGF was added, and incubation was further continued for 2 hours. The incubation mixture was subjected to SDS-polyacrylamide gel electrophoresis under reducing conditions followed by staining with CBB. The results are shown in Fig. 1. In the figure, the numeral 1 indicates the case where neither of HGF activator and the protein was added, 2 indicates the case where HGF activator was added but the protein was not added, and 3 indicates the case where HGF activator and the protein were added. Addition of the protein resulted in suppression of the activity of HGF activator converting single chain HGF to double chain HGF. EXAMPLE 5 (SDS-polyacrylamide gel electrophoresis) For determining the apparent molecular weight of the protein having protease inhibitor activity as purified from the MKN45 cell culture supernatant or A549 cell culture supernatant in Example 1 or Example 2, the protein was subjected to SDS-polyacrylamide gel electrophoresis. The protein finally purified was subjected to SDS-polyacrylamide gel electrophoresis using 12.5% polyacrylamide slab gels, which was conducted under nonreducing conditions. The molecular weight markers used were Molecular weight markers "Daiichi" III for Laemmli method (Daiichi Pure Chemicals). After electrophoresis, color development was performed using a silver stain reagent (Kanto Chemical). Upon relative comparison in migration distance between the protein and the molecular weight markers, the protein obtained from the MKN45 cell culture supernatant or A549 cell culture supernatant showed several fragments or a smear band, presumably due to differences in sugar chain, amino acid residue modification or terminal region, at positions around an apparent molecular weight of about 30,000 daltons as determined by SDS-polyacrylamide gel electrophoresis. EXAMPLE 6 (Cloning of a gene coding for the protein and base sequence determination) The following two oligonucleotide'primers were designed based on a presumption that Xaa will be Cys from the standpoint of the sequences Lys-Val-Val-Gly-Arg-Xaa-Arg and Xaa-Gln-Leu-Phe-Val-Tyr-Gly-Gly selected from the partial amino acid sequence (SEQ ID NO:2 in the sequence listing) of the protein obtained in Example 2. (In the above sequences, N indicates T or G, M indicates A or C, Y indicates T or C, and R indicates A or G.) Then, total RNA was prepared from MKN45 cells by the method described in Anal. Biochem., 162 , 156 (1987) and applied to an oligo(dT)-cellulose column, whereby poly(A)+RNA was obtained. Using the thus-obtained poly(A)+RNA as the template, RT-PCR (reverse transcription-polymerse chain reaction; cf. K. Hayashi (ed.): "PCR Ho no Saishin Gijutu (State-of-art Techniques of PCR)", page 44 and page 52, published Feb. 5, 1995 by Yohdosha) was carried out. The reaction mixture obtained by this RT-PCR was analyzed by polyacrylamide gel electrophoresis, whereupon a DNA fragment of about 85 bp was detected. Therefore, this DNA fragment was extracted from the polyacrylamide gel, followed by phenol-chloroform extraction and ethanol precipitation, whereby the DNA fragment was recovered. The base sequence of the DNA fragment was determined by the dideoxy method. Further, this DNA fragment was labeled with 32 P by the method described in "Molecular Cloning" (Cold Spring Harbor Laboratory, 1982) and used as a screening probe. Using the MKN45 cell line-derived poly(A)+RNA together with a cDNA synthesis kit (Pharmacia), cDNA was synthesized, and a phage library was constructed, as a library for screening, with λ ZAPII (Strategene) as the vector. Escherichia coli XL Blue (Strategene) was infected with the above phage library to give about 100,000 plaques. After overnight culture in NZY medium, the bacterial cells were transferred to a Gene Screening Plus membrane (du pont). The membrane was placed on a filter paper impregnated with 0.1 M sodium hydroxide-0.5 M Tris hydrochloride buffer (pH 7.5) and allowed to stand for 2 minutes and then placed on a filter paper impregnated with 1.5 M sodium chloride-0.5 M Tris hydrochloride buffer (pH 7.5) and allowed to stand for 5 minutes. After two more repetitions of this series of treatments, the membrane was washed with 2 x SSC (two-fold concentrated SSC) and air-dried on a dry filter paper. This membrane was irradiated with UV light at a dose of 120 mJ/cm 2 for fixation of the DNAs transferred to the membrane. The thus-treated membrane was immersed in 50 ml of a solution comprising 50 mM Tris hydrochloride buffer (pH 7.5), 1 M sodium chloride and 1% SDS and maintained in that state at 65°C for 2 hours. Then, the membrane was immersed in 40 ml of a solution comprising 5 ng/ml of the above-mentioned 32 P-labeled probe, 100 µg/ml of salmon sperm, 50 mM Tris hydrochloride buffer (pH 7.5), 1 M sodium chloride and 1% SDS and maintained in that state at 65°C for 16 hours. Thereafter, this membrane was washed with 2 x SSC at room temperature over 5 minutes and then with two portions of 0.1 x SSC at room temperature over 30 minutes, and subjected to autoradiography, which gave 22 positive clones supposedly containing cDNA for the protein. Then, each positive clone was submitted to plasmid construction by the excision method (Toyobo Life Science Catalog, pages 114-115) according to Toyobo Life Science Catalog (pages 114-115) and Strategene's manual. The thus-obtained plasmid DNAs were then cleaved with the restriction enzyme Eco RI and subjected to agarose gel electrophoresis, and a clone with the longest cDNA for the protein inserted therein was selected. Then, by analyzing the base sequence of the plasmid (pHAI-II) harbored by this clone, the whole base sequence of the gene coding for the protein was determined (SEQ ID NO:4 in the sequence listing). EXAMPLE 7 (Preparation of an expression plasmid for the protein) A 10-µg portion of the plasmid (pHAI-II) containing the cDNA for the protein as obtained in Example 6 was subjected to cleavage with the restriction enzyme Eco RI, followed by agarose gel electrophoresis. Thus, an about 1.4 kb Eco RI- Eco RI DNA fragment containing the cDNA for the protein was separated and extracted. The thus-obtained DNA fragment was rendered blunt-ended by the conventional method using T4 DNA polymerase and, then, the DNA fragment was purified by phenol-chloroform extraction and ethanol precipitation and dissolved in 10 µl of water. Separately, 0.05 µg of the expression vector pME18S (Medical Immunology, 20 , 27 (1990)) was cleaved in advance with the restriction enzyme Xho I, and the DNA fragment obtained was rendered blunt-ended by the conventional method using T4 DNA polymerase and then purified by phenol-chloroform extraction and ethanol precipitation. This was dissolved in 400 µl of a 1 mM MgCl 2 solution in 50 mM Tris-HCl (pH 8), 1 unit of bacterial alkaline phosphatase (Toyobo, BAP-101) was added, and dephosphorylation treatment was conducted at 65°C for 30 minutes. Then, the DNA fragment was purified from'this reaction mixture by phenol-chloroform extraction and ethanol precipitation and dissolved in 10 µl of water. Ligation reaction was carried out in 20 µl of a reaction mixture (66 mM Tris-HCl, pH 7.6, 6.6 mM MgCl 2 , 10 mM dithiothreitol, 66 µM ATP) containing 0.01 µg of the pME18S vector-derived DNA fragment prepared as mentioned above and 0.1 µg of the above-mentioned blunt-ended EcoRI fragment of cDNA for the protein in the presence of T4 DNA ligase (Toyobo LGA-101) at 14°C for 12 hours. A 10-µl portion of this T4 DNA ligase reaction mixture was used to transform Escherichia coli HB101 (Takara Shuzo) according to the manual attached thereto. The microorganism was cultured on a medium containing 50 µg/ml of ampicillin and scores of ampicillin-resistant strains were obtained. These transformants were analyzed by the method of Maniatis et al. ("Molecular Cloning", Cold Spring Harbor Laboratory, pages 86-96 (1982)) and, as a result, a plasmid, pME18S-HAI-II, containing the gene coding for the protein as inserted at the Xho I restriction enzyme cleavage site occurring between the promoter and polyadenylation site of the expression vector pME18S could be obtained. Its structure is shown in Fig. 2. EXAMPLE 8 (Obtaining of a cell line expressing the protein) The plasmid pME18S-HAI-II constructed in Example 7 and containing the cDNA for the protein as inserted at the Xho I restriction enzyme cleavage site of the expression vector pME18S was recovered and purified from the recombinant Escherichia coli by the method of Maniatis et al. ("Molecular Cloning", Cold Spring Harbor Laboratory, pages 86-96 (1982)) and thus a large amount of the expression plasmid DNA for the protein was obtained. COS cells were transformed by transfection thereof with the expression plasmid DNA. Thus, COS cells were first cultured in eRDF medium containing 10% FBS (fetal bovine serum) in tissue culture dishes 9 cm in diameter until a semiconfluent condition. Then, the medium was removed from the dishes, and a DNA solution prepared as mentioned below was added dropwise thereto as mentioned below. First, for each dish 9 cm in diameter, a solution was prepared in an Eppendorf centrifuge tube by adding thereto 300 µl of 2 x HEBS solution (2 x HEBS solution: 1.6% sodium chloride, 0.074% potassium chloride, 0.05% disodium hydrogen phosphate dodecahydrate, 0.2% dextrose, 1% HEPES (pH 7.05)) and 10 µg of the plasmid DNA and making the volume 570 µl with sterilized water. Then, while adding 30 µl of 2.5 M calcium chloride solution to the DNA solution, the tube contents were stirred vigorously using a vortex mixer for several seconds. The resulting mixture was allowed to stand at room temperature for 30 minutes, with occasional stirring at intervals of about 10 minutes using a vortex mixer. The thus-prepared DNA solution was laid on the cells mentioned above and the whole was allowed to stand at room temperature for 30 minutes. Then, 9 ml of eRDF medium (Kyokuto Pharmaceutical) supplemented with 10% FBS was added to each dish and incubation was performed at 37°C for 4 to 5 hours in the presence of 5% CO 2 . Then, the medium was removed from each dish and the cells were washed with 5 ml of 1 x TBS++ solution (1 x TBS++ solution: 25 mM Tris-hydrochloride (pH 7.5), 140 mM sodium chloride, 5 mM potassium chloride, 0.6 mM disodium hydrogen phosphate, 0.08 mM calcium chloride, 0.08 mM magnesium chloride). After removing the 1 x TBS++ solution, the cells were covered with 5 ml/dish of 1 x HEBS solution containing 10% DMSO (dimethyl sulfoxide) and allowed to stand at room temperature for 1 to 2 minutes. The supernatant was then removed. The cells were again washed with 5 ml of 1 x TBS++ solution, 10 ml of eRDF medium supplemented with 10% FBS was added to each dish and incubation was performed at 37°C in the presence of 5% CO 2 . After the lapse of 48 hours, the medium was recovered. The supernatant recovered was 20-fold concentrated and assayed for inhibitory activity against HGF activator in the same manner as in Example 4. The inhibitory activity was confirmed. While the invention has been described in detail and with reference to specific embodiments thereof, it will be apparent to one skilled in the art that various changes and modifications can be made therein without departing from the spirit and scope thereof. SEQUENCE LISTING (1) GENERAL INFORMATION: (i) APPLICANT: (A) NAME: MITSUBISHI CHEMICAL CORPORATION (B) STREET: 5-2, Marunouchi 2-chome, Chiyoda-ku (C) CITY: Tokyo (E) COUNTRY: Japan (F) POSTAL CODE (ZIP): none (ii) TITLE OF INVENTION: NOVEL PROTEIN, DNA CODING FOR SAME AND METHOD OF PRODUCING THE PROTEIN (iii) NUMBER OF SEQUENCES: 7 (iv) COMPUTER READABLE FORM: (A) MEDIUM TYPE: Floppy disk (B) COMPUTER: IBM PC compatible (C) OPERATING SYSTEM: PC-DOS/MS-DOS (D) SOFTWARE: PatentIn Release #1.0, Version #1.30 (EPO) (v) CURRENT APPLICATION DATA: APPLICATION NUMBER: EP 96 111 861.9 (2) INFORMATION FOR SEQ ID NO: 1: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 15 amino acids (B) TYPE: amino acid (C) STRANDEDNESS: (D) TOPOLOGY: linear (ii) MOLECULE TYPE: peptide (v) FRAGMENT TYPE: N-terminal (vi) ORIGINAL SOURCE: (A) ORGANISM: Homo sapiens (B) STRAIN: MKN45 (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 1: (2) INFORMATION FOR SEQ ID NO: 2: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 29 amino acids (B) TYPE: amino acid (C) STRANDEDNESS: (D) TOPOLOGY: linear (ii) MOLECULE TYPE: peptide (v) FRAGMENT TYPE: internal (vi) ORIGINAL SOURCE: (A) ORGANISM: Homo sapiens (B) STRAIN: MKN45 (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 2: (2) INFORMATION FOR SEQ ID NO: 3: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 26 amino acids (B) TYPE: amino acid (C) STRANDEDNESS: (D) TOPOLOGY: linear (ii) MOLECULE TYPE: peptide (v) FRAGMENT TYPE: internal (vi) ORIGINAL SOURCE: (A) ORGANISM: Homo sapiens (B) STRAIN: MKN45 (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 3: (2) INFORMATION FOR SEQ ID NO: 4: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 759 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: double (D) TOPOLOGY: linear (ii) MOLECULE TYPE: cDNA to mRNA (iv) ANTI-SENSE: NO (vi) ORIGINAL SOURCE: (A) ORGANISM: Homo sapiens (B) STRAIN: MKN45 (ix) FEATURE: (A) NAME/KEY: CDS (B) LOCATION:1..756 (C) IDENTIFICATION METHOD: experimental (D) OTHER INFORMATION:/evidence= EXPERIMENTAL (ix) FEATURE: (A) NAME/KEY: sig_peptide (B) LOCATION:1..81 (C) IDENTIFICATION METHOD: experimental (D) OTHER INFORMATION:/evidence= EXPERIMENTAL (ix) FEATURE: (A) NAME/KEY: mat_peptide (B) LOCATION:82..756 (C) IDENTIFICATION METHOD: experimental (D) OTHER INFORMATION:/evidence= EXPERIMENTAL (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 4: (2) INFORMATION FOR SEQ ID NO: 5: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 252 amino acids (B) TYPE: amino acid (D) TOPOLOGY: linear (ii) MOLECULE TYPE: protein (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 5: (2) INFORMATION FOR SEQ ID NO: 6: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 20 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (ii) MOLECULE TYPE: other nucleic acid (A) DESCRIPTION: /desc = "synthetic DNA" (ix) FEATURE: (A) NAME/KEY: misc_feature (B) LOCATION:group(6, 9, 12, 15) (D) OTHER INFORMATION:/note= "N is T or G" (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 6: (2) INFORMATION FOR SEQ ID NO: 7: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 21 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (ii) MOLECULE TYPE: other nucleic acid (A) DESCRIPTION: /desc = "synthetic DNA" (ix) FEATURE: (A) NAME/KEY: misc_feature (B) LOCATION:group(2, 8, 14) (D) OTHER INFORMATION:/note= "N is T or G" (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 7:

Claims: A protein having the following physio-chemical properties: (1) inhibitory activity on the protease activity of hepatocyte growth factor activator; and (2) the amino acid sequence depicted in the sequence listing under SEQ ID NO: 2. A protein according to claim 1, further having a molecular weight of about 30,000 daltons as determined by SDS-polyacrylamide gel electrophoresis. A protein according to claim 1 or 2, wherein the amino acid sequence is selected from the sequence depicted in the sequence listing under SEQ ID NO: 4 A protein according to claim 1 or 2, wherein the amino acid sequence is a segment of the amino acid sequence depicted in the sequence listing under SEQ ID NO: 4 which starts with the 28 th amino acid (alanine) residue and ends with the 252 nd amino acid (leucine) residue. A method of producing a protein according to one of claims 1 to 4 which comprises cultivating MKN45 cells or A549 cells under conditions contributing to the expression of the protein and isolating the protein from the culture supernatant.

Inventors: KAWAGUCHI TOSHIYA, KITAMURA NAOMI, SHIMOMURA TAKESHI, KAWAGUCHI, TOSHIYA, KITAMURA, NAOMI, SHIMOMURA, TAKESHI, Kawaguchi, Toshiya, c/o Mitsubishi Chem. Corp., Shimomura, Takeshi, c/o Mitsubishi Chem. Corp.
Applicants: MITSUBISHI CHEM CORP, MITSUBISHI CHEMICAL CORPORATION
Application year: 1996
Main classification: C12N15
IPC codes: C07K14, C12N15